ProQR Therapeutics NV (NASDAQ:PRQR) has earned an average rating of “Buy” from the nine analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $30.40.

A number of analysts recently issued reports on PRQR shares. Cantor Fitzgerald set a $40.00 price target on ProQR Therapeutics and gave the company a “buy” rating in a report on Tuesday, January 29th. ValuEngine lowered ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 13th. Chardan Capital restated a “buy” rating and set a $25.00 target price (up previously from $21.00) on shares of ProQR Therapeutics in a report on Tuesday, March 12th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of ProQR Therapeutics in a research report on Thursday, February 28th. Finally, BidaskClub raised ProQR Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 7th.

Shares of NASDAQ PRQR opened at $11.01 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.08 and a quick ratio of 10.08. ProQR Therapeutics has a 52-week low of $4.40 and a 52-week high of $24.00.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15. On average, research analysts predict that ProQR Therapeutics will post -1.58 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. Lindbrook Capital LLC acquired a new stake in ProQR Therapeutics during the 4th quarter worth about $25,000. Barclays PLC acquired a new stake in ProQR Therapeutics during the 4th quarter worth about $51,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in ProQR Therapeutics during the 4th quarter worth about $53,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in ProQR Therapeutics during the 4th quarter worth about $124,000. Finally, Deutsche Bank AG acquired a new stake in ProQR Therapeutics during the 4th quarter worth about $137,000. 60.19% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Recommended Story: Resistance Level

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.